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Extracellular Adherence Protein of Staphylococcus
aureus Suppresses Disease by Inhibiting T-Cell
Recruitment in a Mouse Model of Psoriasis
Honglin Wang1,2, Julia von Rohrscheidt2, Jan Roehrbein2, Thorsten Peters2, Anca Sindrilaru2, Daniel Kess2,
Klaus T. Preissner3 and Karin Scharffetter-Kochanek2
Psoriasis is a T-cell-mediated inflammatory disease. Previous studies focused on lymphocyte function-
associated antigen 1 (LFA-1)-expressing T cells as a molecular target for therapeutic intervention. By contrast,
information on therapeutic effects and the underlying mechanism of blocking the LFA-1 counter receptor,
ICAM-1 is scarce. Here, we used the CD18 (b2-integrin) hypomorphic (CD18
hypo) mouse model of psoriasis to
investigate the therapeutic role of extracellular adherence protein (Eap) of Staphylococcus aureus, which exerts
antiinflammatory activities by interacting with the ICAM-1 function. We show that ICAM-1 is predominantly
upregulated on endothelial cells in lesional skin of CD18hypo mice. In vitro Eap was found to disrupt cell–cell
contacts between T cells and dendritic cells, and inhibit T-cell proliferation. By contrast, in vivo Eap rather
blocked transmigration of T cells from vessels to inflamed skin of CD18hypo mice, but did not inhibit their
proliferation and activation. Most importantly, Eap successfully suppressed the disease by blocking T-cell
extravasation into the inflamed skin. Together, these data indicate that interaction between LFA-1 and ICAM-1 is
causally involved in the pathogenesis of psoriasiform skin inflammation, and targeting ICAM-1 to selectively
block T-cell extravasation by Eap without immune suppression may represent a potential therapeutic strategy
for psoriasis.
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INTRODUCTION
Psoriasis vulgaris is a chronic inflammatory skin disorder with
an incidence of 2–3% in the general population; however, its
pathogenesis is not well understood (Nickoloff and Nestle,
2004). An abnormal function of T lymphocytes has been
proposed as a potential cause of psoriasis (Conrad et al.,
2007). Research into the pathogenesis of human psoriasis has
profited at least in part from suitable animal models (Schon,
2008). Previously, we reported a polygenic mouse model that
develops a T-cell-mediated psoriasiform skin disease in
homozygous CD18 hypomorphic (CD18hypo) PL/J mice with
a severe reduction of CD18 expression to only 2–16% of
wild-type (wt) levels (Wilson et al., 1993; Bullard et al., 1996;
Wang et al., 2006, 2008). This murine psoriasis model
strongly resembles human psoriasis clinically and histologi-
cally, in its T-cell-dependent pathogenesis, its polygenic
base, and its response to therapy (Bullard et al., 1996).
Affected mice present with erythema, scaling, and crusts
together with abnormal keratinocyte proliferation/differentia-
tion, subcorneal microabscesses, and an increased inflam-
matory infiltrate (Bullard et al., 1996). CD4þ T cells, but not
CD8þ T cells, are crucial for the pathogenesis of the skin
disorder in this mouse model of psoriasis (Kess et al., 2003).
Adhesive and signaling events, including selectin-
mediated rolling, chemoattractant-induced integrin activa-
tion, integrin-dependent firm adhesion, and the subsequent
transendothelial migration, are required for lymphocyte
extravasation (Springer, 1994). The interaction between
lymphocyte function-associated antigen 1 (LFA-1) and
ICAM-1 is critical in these adhesive and signaling processes
for T lymphocyte recirculation, trafficking to sites of
inflammation, antigen (Ag) presentation by dendritic cells
(DCs) (Hogg et al., 2003), and T cell co-stimulation (Van
Seventer et al., 1990). LFA-1 is a heterodimeric glycoprotein
belonging to the b2-integrin family (Carlos and Harlan, 1994),
& 2010 The Society for Investigative Dermatology www.jidonline.org 743
ORIGINAL ARTICLE
Received 29 April 2009; revised 12 August 2009; accepted 17 August 2009;
published online 8 October 2009
1Shanghai Institute of Immunology, Institute of Medicine Science, Shanghai
Jiao Tong University School of Medicine, Shanghai, PR China; 2Department
of Dermatology and Allergic Diseases, University of Ulm, Ulm, Germany and
3Institute for Biochemistry, Medical School, Justus-Liebig-University, Giessen,
Germany
Correspondence: Professor Karin Scharffetter-Kochanek, Department of
Dermatology and Allergic Diseases, University of Ulm, Maienweg 12, D-
89081 Ulm, Germany. E-mail: karin.scharffetter-kochanek@uniklinik-ulm.de
Abbreviations: Ab, antibody; Ag, antigen; CD18hypo, CD18 hypomorphic;
CFSE, carboxyfluorescein succinimidyl ester; DC, dendritic cell; Eap,
extracellular adherence protein of Staphylococcus aureus; LFA-1, lymphocyte
function-associated antigen 1; PASI, psoriasis area and severity index; TNF-a,
tumor necrosis factor-a; Treg, regulatory T cell; Tresp, responder T cell; wt,
wild-type
also known as aL-b2 or CD11a/CD18, and expressed on
leukocytic cells, particularly on T cells. LFA-1 mediates
leukocyte adhesion to endothelial cells lining vessels by
binding to ICAM 1–3 (ICAM-1, ICAM-2, and ICAM-3). Many
studies have focused on LFA-1 as a molecular target for
therapeutic intervention of immune responses in murine
models of autoimmune diseases (Gordon et al., 1995;
Moriyama et al., 1996) as well as in human psoriasis
(Lebwohl et al., 2003). However, the therapeutic effects
and mechanisms of targeting the LFA-1–ICAM-1 interaction
by blocking the LFA-1 counter receptor ICAM-1 are
undefined in chronic skin inflammations including psoriasis.
This issue may be important as LFA-1–ICAM-1 interaction is
engaged in the transendothelial migration of pathogenic T
cells and interaction between Ag-presenting DCs and various
T-cell subsets (Wang et al., 2008).
Extracellular adherence protein (Eap), also designated as
MHC class II analogous protein or P70, is a secreted protein
from S. aureus. Eap exhibits a broad repertoire of binding to a
number of different extracellular matrix glycoproteins, includ-
ing bone sialoprotein, fibronectin, and fibrinogen (Chavakis
et al., 2005). Eap was previously reported to exert a direct
interaction with ICAM-1 that resulted in the disruption of
integrin-dependent neutrophil–endothelial interactions (Chava-
kis et al., 2002). More recently, Eap has been shown to prevent
the development of experimental autoimmune encephalomye-
litis by inhibiting the LFA-1–ICAM-1 interaction between T cells
and endothelial cells (Xie et al., 2006).
The CD18hypo mouse model of psoriasis develops a CD4þ
T-cell-mediated psoriasiform skin disease (Kess et al., 2003).
The role of CD18 involved in expansion and function of
distinct T-cell subsets in the control of autoimmunity has
recently been studied (Marski et al., 2005; Wang et al., 2008).
In CD18null mice with the complete CD18 deficiency neither
CD4þCD25þ regulatory T (Treg) nor CD4þCD25 respon-
der T (Tresp) cells can migrate into the skin (Kess et al., 2003).
Such migration does occur in the CD18hypo mice with the
reduced expression of CD18, thus allowing studies on LFA-
1–ICAM-1-mediated interactions in the development of the
psoriasiform skin disease. These studies have identified a
defective immune synapse formation between DCs and Treg
to be responsible for the lack of suppressive function of Treg
and the uncontrolled activation of pathogenic Tresp cells
driving the development of the disease (Wang et al., 2008).
This model offers a unique opportunity to study the effect of
Eap at different ICAM-1-dependent cell–cell interactions in
the chronic skin inflammation in vivo.
Here, we have found that endothelial cells in psoriatic skin
of the CD18hypo mice, but not of CD18wt mice, predomi-
nantly express ICAM-1, which is critically required for T-cell
transmigration into the lesional skin of CD18hypo mice, and
adoptive transfer of pathogenic Tresp cells derived from
affected CD18hypo mice induced disease in healthy CD18hypo
mice. Strikingly, Eap did not seem to inhibit the activation
and/or proliferation of either Treg or Tresp cells in vivo,
whereas it suppressed the psoriasiform skin disorder by
blocking T-cell transmigration to inflamed skin. Our data
suggest that blocking the ICAM-1 function is critical for the
emigration of pathogenic T cells, promoting the psoriasiform
skin disease, and targeting T-cell recruitment by Eap may
represent a strategy for the effective treatment of chronic
inflammatory skin diseases, such as psoriasis, without the
induction of side effects such as immunosuppression.
RESULTS
The psoriasiform skin disorder is induced by adoptive transfer of
CD18hypo Tresp cells into healthy CD18hypo mice
We previously found that the depletion of CD4þ T cells by
neutralizing antibodies (Abs) resulted in a complete resolu-
tion of psoriasiform skin inflammation in CD18hypo mice
(Kess et al., 2003). To further study the contribution of the
T-cell subset of CD4þCD25 Tresp cells for the development
of the disease, we transferred 5–10 106 purified Tresp cells
derived from affected CD18hypo mice or CD18wt mice into
healthy CD18hypo recipients. Ten days after transfer of Tresp
cells, all four recipients developed erythema on the ears as
well as erythema, scales, and hair loss on the forehead
(Figure 1a). This phenotype was more pronounced 20 days
after adoptive transfer of CD18hypo Tresp cells (Figure 1a). By
contrast, the transfer of Tresp cells from either CD18wt or
healthy CD18hypo failed to produce the psoriasiform skin
disease (data not shown). 3[H]-thymidine incorporation
assays performed after T-cell activation with anti-CD3 and
anti-CD28 mAbs further showed that Tresp cells derived from
affected CD18hypo mice had a significantly higher prolifera-
tion compared with Tresp cells derived from CD18wt mice
(P¼0.0047) and healthy CD18hypo mice (P¼ 0.008) (Supple-
mentary Figure S2). These data may indicate that Tresp
derived from CD18hypo affected mice are preactivated to a
higher extent compared with that of CD18hypo healthy mice,
whereas no preactivation is expected in Tresp cells from
CD18wt mice. In fact, we earlier showed that Tresp cells from
CD18hypo affected mice released increased concentrations of
IL-2, IL-12, and IFN-g (Kess et al., 2003). Immunofluores-
cence staining showed an accumulation of CD4þ T cells, but
neither macrophages (F4/80 staining) nor tumor necrosis
factor-a (TNF-a) expression were observed at day 5 after
injection of Tresp cells. At day 10, both CD4þ T cells and
macrophages, as well as strong TNF-a expression were
detected (Figure 1b-d). Together with previous observations
(Kess et al., 2003; Wang et al., 2006), our data suggest that
the reduced CD18 expression is sufficient for the transmigra-
tion of CD4þ T cells into the skin. As CD4þ T cells precede
and are responsible for recruitment and activation of
macrophages, and depletion of CD4þ T cells results in the
complete resolution of the psoriasiform skin disease (Kess
et al., 2003), blocking the CD4þ T-cell emigration and
trafficking to sites of inflammation represents a potent strategy
for successful treatment of the disease.
ICAM-1 expression is highly upregulated on endothelial cells in
the lesional skin of CD18hypo mice
In psoriatic lesions of patients suffering from human psoriasis,
ICAM-1 staining has been described to be strongly expressed
on endothelial cells as well as on the surface of epidermal
keratinocytes above the dermal papilla (Terajima et al.,
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1998). In agreement with this study on psoriasis patients, we
observed a faint staining on the basal epidermal keratinocytes
or on inflammatory infiltrates in the dermis of the lesional
skin derived from CD18hypo mice (Figure 2a, white arrows). A
much stronger staining for ICAM-1 was observed on CD31þ
endothelial cells (Figure 2a, yellow staining). By contrast, in
the skin derived from CD18wt mice, the staining for ICAM-1
is almost undetectable with the exception of a clear single
staining for CD31þ endothelial cells (Figure 2b, red staining).
These data indicate that ICAM-1 is strongly upregulated,
particularly on endothelial cells in CD18hypo mice, and most
likely contributes to an increased adhesion of pathogenic
T cells to endothelial cells with subsequent emigration
driving the psoriasiform skin phenotype.
Injection of Eap resolves the psoriasiform phenotype in
CD18hypo mice
To investigate whether Eap influences the T-cell-mediated
psoriasiform skin disease in the CD18hypo mouse model of
psoriasis, affected CD18hypo mice were injected intraperito-
neally with recombinant Eap at a daily dose of 50mg per
200ml or with buffer as control. Injection of Eap in CD18hypo
mice with a severe inflammatory phenotype (Figure 3a left)
led to a remarkable improvement of the inflammatory skin
disease after 35 days of treatment (Figure 3a right). The
reduction in severity and extent of erythema, plaque
formation, and scaling after treatment with Eap was highly
significant, as assessed by the adapted psoriasis activity and
severity index (PASI) score (7.2±1.48 versus 3.4±2.07;
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Figure 1. Adoptive transfer of CD18 hypomorphic (CD18hypo) CD4þCD25 responder T (Tresp) cells into healthy CD18hypo mice induces the psoriasiform
skin disease. To study the contribution of Tresp cells to the development of psoriasiform skin disease in CD18hypo mouse model of psoriasis, we transferred
5–10106 purified Tresp cells derived from spleens of affected CD18hypo mice into healthy CD18hypo recipients. (a) Clinical pictures of one representative
mouse at day 0, day 10, and day 20 after injection of Tresp cells. (b–d) Immunostaining using CD4 (green), F4/80 (green), and tumor necrosis factor-a
(TNF-a) (red) mAb was performed as described in Material and Methods. Original magnification  40. Bar¼20 mm. e, epidermis; d, dermis; h, hair follicle.
Dotted lines indicate the border between epidermis and dermis.
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P¼0.0125) (Figure 3b) (Kess et al., 2003). In contrast, no
significant change in the adapted PASI scores was observed
in four mice treated with buffer only (P¼ 0.5973) (Figure 3c).
Furthermore, injection of BSA with a molecular weight of
66 kDa with that of Eap did not result in any improvement, as
assessed by the adapted PASI score (data not shown). This
finding rules out a confounding immunological variable
mediating the effects from the Eap protein injections.
Together, our data indicate that the resolution of the
psoriasiform skin disease after Eap injection may be due to
the inhibition of the recruitment of pathogenic T cells, to the
decreased activation of pathogenic T cells by Ag-presenting
cells, or to a combination thereof.
Inflammatory cell infiltrates and production of TNF-a are
decreased by Eap in the skin of CD18hypo mice
CD4þ T-cell infiltration and activation in the lesional skin of
CD18hypo mice is pivotal for induction of the disease (Kess
et al., 2003), and precedes the recruitment and activation
of macrophages, which constitute an important source of
TNF-a in the lesional skin of affected CD18hypo mice (Wang
et al., 2006). To study whether Eap treatment indeed results in
reduction or inhibition of the recruitment of pathogenic
CD4þ T cells that are responsible for the recruitment
and activation of macrophages, immunostaining for CD4þ
T cells, macrophages, and TNF-a was performed on skin of
affected mice that were either injected with control buffer or
injected with Eap. In the skin of mice injected with buffer,
abundant infiltration of CD4þ T cells, F4/80þ macrophages,
and TNF-aþ cells were found (Figure 4a, d, g). By contrast,
35 days after treatment with Eap, we observed a significant
reduction in CD4þ T cells, F4/80þ macrophages, and
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Figure 2. Endothelial cells express high levels of ICAM-1 in the lesional skin
of CD18 hypomorphic (CD18hypo) mice. Cryosections from lesional skin of
CD18hypo mice (a) or skin of CD18wt mice (b) were stained with CD31 (red)
and ICAM-1 (green) mAbs for their expression. Overlay (yellow) represents
double-positive cells depicting endothelial cells expressing high levels of
ICAM-1 in the lesional skin of CD18hypo mice. Cell nuclei (blue) were
counterstained with 40,6-diamidino-2-phenylindole (DAPI) (original
magnification  40). Bar¼20 mm. e, epidermis; d, dermis; h, hair follicle.
White arrows mark the faint staining of ICAM-1 on the basement membrane
adjacent site of basal epidermal keratinocytes in the lesional skin derived from
CD18hypo mice. Dotted lines indicate the border between epidermis and
dermis. One representative experiment out of six is shown.
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Figure 3. Extracellular adherence protein (Eap) improves the psoriasiform
phenotype in affected CD18 hypomorphic (CD18hypo) mice. Mice were
administered intraperitoneally with recombinant Eap at a dose of 50 mg per
200ml or with buffer daily. (a) Representative clinical pictures of an affected
CD18hypo mouse with severe psoriasiform skin disease before (left) and after
35 days of treatment with Eap (right). The severity of the psoriasiform
phenotype as assessed by the adapted psoriasis area and severity index score
was significantly reduced after Eap treatment (b) (P¼ 0.0125 by Student’s
t-test) but not after treatment with buffer (P¼0.5973 by Student’s t-test) (c).
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TNF-aþ cells (Figure 4b, e, h). The numbers of CD4þ T cells,
F4/80þ macrophages, and TNF-aþ cells were significantly
decreased in CD18hypo mice injected with Eap compared
with the buffer-injected controls (Figure 4c, f, i). We have
also observed that MCP-1, which was previously identified to
be critical for the strong infiltration of macrophages in the
skin of CD18hypo mice (Wang et al., 2006), was decreased by
the Eap treatment (Supplementary Figure S3). This may lead
to a decrease in the infiltration of macrophages. In addition, a
decrease in the numbers of Ki67þ cells was detected after
Eap injection compared with the injection of buffer
(Figure 4j-l), suggesting that blocking of pathogenic CD4þ
T-cell recruitment by Eap with inhibition of macrophage
activation and TNF-a release resulted in an improvement of
psoriasiform skin disease, which was accompanied by a
marked decrease in the numbers of Ki67þ proliferating
cells, both in the dermis and the epidermis (Wang et al.,
2006).
Eap disrupts the interaction between T cell and DC in vitro, but
does not inhibit the allogeneic activation and proliferation of
T cells in vivo
As Eap blocks the adhesion of T cells to ICAM-1 (Xie et al.,
2006), we studied whether Eap impairs the contacts between
DC and CD4þ T-cell subsets, CD4þCD25þ Treg cells, and
CD4þCD25 Tresp cells in vitro. Mixed lymphocyte reac-
tions were performed with either Treg or Tresp cells from PL/J
CD18wt (H-2u) mice together with allogeneic DC from
C57BL/6J CD18wt (H-2b) mice in the presence of recombi-
nant murine IL-2, without or with Eap. Interestingly, Eap
concentration-dependently diminished cell–cell contacts
between allogeneic DCs and CD18wt Treg (Figure 5a) or
Tresp cells (Figure 5c). In the presence of Eap at 20 mgml1,
cluster formation with allogeneic DC was significantly
reduced for either Treg or Tresp cells derived from CD18wt
mice (Figure 5b, d). Similarly, the proliferation of both Treg
and Tresp cells is dose-dependently decreased by Eap in
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Figure 4. Extracellular adherence protein (Eap) decreases cell infiltrates and production of tumor necrosis factor-a (TNF-a) in the skin of CD18 hypomorphic
(CD18hypo) mice. Cryosections from skin of CD18hypo mice treated with buffer (a, d, g, j) or Eap (b, e, h, k) were stained with CD4 (green), F4/80 (green), TNF-a
(red), and Ki67 (red) for their expression. Cell nuclei (blue) were counterstained with 40,6-diamidino-2-phenylindole (DAPI). Original magnification  20.
Bar¼40 mm. e, epidermis; d, dermis; h, hair follicle. Dotted lines indicate the border between epidermis and dermis. (c, f, i, l) To quantify CD4þ , F4/80þ ,
TNF-aþ , and Ki67þ cells in the skin of affected CD18hypo mice treated with buffer or Eap, the positively stained cells were counted. For all measurements,
the median of specifically stained cells counted in 15 high-power fields is presented (n¼ 5). (*Po0.05, **Po0.01, Student’s t-test).
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mixed lymphocyte reactions (Figure S4). As a control, we
studied whether Eap at concentrations of up to 20 mgml1 are
cytotoxic for T cells in culture. CD4þ T cells derived from PL/J
CD18wt mice were stimulated with 10 mgml1 soluble anti-
CD3 and 2 mgml1 anti-CD28 mAbs in presence of various
Eap concentrations. We found a similar induction of T-cell
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Figure 5. Extracellular adherence protein (Eap) disrupts the interaction between T cells and dendritic cells (DCs) in vitro, but does not inhibit the activation
and proliferation of T-cell subsets in vivo. Regulatory T (Treg) or responder T (Tresp) cells were purified from spleens of PL/J CD18wt mice using magnetic-
activated cell sorting (MACS), and co-cultured with irradiated allogeneic DCs derived from C57BL/6J mice. (a, c) Representative pictures of cluster formation of
allogeneic DCs with Treg or Tresp cells derived from PL/J CD18wt in presence of different concentrations of Eap are shown. Original magnification  40.
Bar¼20 mm. (b, d) Cluster formation between allogeneic DCs and Treg or Tresp cells in the presence of Eap was assessed by counting aggregated clusters per
high-power field (HPF) in 100 randomly selected HPFs (*Po0.05, **Po0.01 by Student’s t-test). One representative experiment in triplicate out of three
independent experiments is shown (e, f). 1 106 Treg or Tresp cells derived from C57BL/6J CD18wt mice were labeled with carboxyfluorescein succinimidyl
ester (CFSE) and injected intraperitoneally into PL/J CD18wt or C57BL/6J CD18wt mice. Immediately after the injection of Treg or Tresp cells, 50 mg Eap or buffer
was injected intraperitoneally into PL/J CD18wt recipients every day. FACS analysis was performed to measure proliferation of CFSE-labeled Treg or Tresp cells
from peritoneum of recipient mice. (g) CFSE-labeled cells were gated out for CD25 expression by FACS analysis. One representative experiment out of two
independent experiments is shown.
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proliferation in all settings, indicating that Eap, even at
concentrations of up to 20 mgml1, is not cytotoxic for T cells
in in vitro culture (Figure S5). Collectively, these data clearly
show that Eap is sufficient to inhibit the interaction between
ICAM-1 and its T-cell counter receptor, LFA-1, and thus
suppress the subsequent expansion of distinct allogenically
stimulated T-cell subsets in vitro.
In the herein used CD18hypo psoriasis model, the auto-
antigen is unknown. Therefore, it is difficult to study the time
kinetics of the Ag presentation of DCs to Treg and Tresp cells,
and it is difficult to assess the impact of Eap on these
pathogenic key events in vivo. To circumvent this difficulty
and to examine whether Eap interferes with DC–T-cell subset
interactions in vivo, a graft versus host model was used (Firan
et al., 2006). A total of 1 106 Treg or Tresp cells derived
from C57BL/6J CD18wt (H-2b) mice were labeled with
carboxyfluorescein succinimidyl ester (CFSE) and injected
intraperitoneally into PL/J CD18wt (H-2u) mice. Immediately
after injection of T cells, 50 mg Eap or buffer was injected
intraperitoneally into CD18wt recipients every day. Peritoneal
cells were harvested and assessed for proliferation of CFSE-
labeled Treg and Tresp cells 3 days after T-cell transfer.
Strikingly, we did not observe any decrease in proliferation,
as assessed by numbers of CFSE-labeled Treg and Tresp cells
in recipients injected with Eap compared with recipients
injected with buffer only (Figure 5e). Even at a higher Eap
concentration of 100mgml1, no effect on the activation of
T-cell subsets was seen (data not shown). As controls, we
injected CSFE-labeled Treg or Tresp cells derived from
C57BL/6J CD18wt mice into the peritoneum of C57BL/6J
CD18wt mice together with Eap or buffer. Almost no
proliferation of T cells occurred (Figure 5f). Additionally, in
contrast to the buffer-injected controls, no decrease in CD25
expression was found in CD18wt recipients injected with Eap,
indicating that the activation of Tresp cells was not blocked
by Eap (Figure 5g, left two panels). As another control, we
injected Tresp cells derived from C57BL/6J CD18wt mice to
C57BL/6J CD18wt recipients; no activation of Tresp was
observed in both Eap and buffer-treated C57BL/6J CD18wt
recipients (Figure 5g, right two panels). Collectively, these
data suggest that the injection of Eap at the indicated
concentration does not block allogeneic activation and
proliferation of T cells in vivo.
The migration of T cells to inflamed skin is decreased by Eap in
affected CD18hypo mice
As Eap obviously did not affect the DC–T-cell subset
interaction in vivo, we were interested in the cause of the
overall beneficial effect of Eap in the treatment of the
psoriasiform skin disease. Previous studies suggested that Eap
may serve as a new antiinflammatory therapeutic substance
to block leukocyte extravasation in patients (Chavakis et al.,
2002). To study whether Eap blocks the migration of
pathogenic Tresp cells into the lesional skin of CD18hypo
mice, we transferred CFSE-labeled 5–10106 CD18hypo
Tresp cells into affected CD18hypo mice by i.v. injection into
the tail veins. Immediately after adoptive transfer of Tresp
cells, 50 mg Eap or buffer was injected intraperitoneally into
affected CD18hypo recipients every day. Numbers of CFSE-
labeled Tresp cells from blood of affected recipients were
significantly reduced in control mice as compared with mice
treated with Eap (Figure 6a), suggesting that administration of
Eap inhibits the extravasation of T cells in vivo, and the
increase in circulating lymphocytes may reflect decreased T-
cell emigration into skin as a result of the endothelial ICAM-1
blockade.
Intercellular adhesion molecule 1 has been reported to be
the major endothelial guard for LFA-1-dependent entry of T
cells into inflamed tissue (Lehmann et al., 2003). To prove
that Eap indeed blocked the recruitment of T cells into
inflamed skin of CD18hypo mice, we adoptively transferred
CFSE-labeled CD18hypo Tresp cells into CD18hypo mice, as
CFSE labeling can be used to trace the transferred cells in the
lesional skin of CD18hypo recipients. Notably, 7 days after i.v.
adoptive transfer, we observed that the CD18hypoCFSEþ cells
were abundantly recruited to the skin derived from affected
CD18hypo recipients injected with buffer, whereas only few
CD18hypoCFSEþ cells were observed in the skin derived from
affected CD18hypo recipients injected with Eap (Figure 6b). In
addition, the number of CD18hypoCFSEþ cells in the skin of
CD18hypo mice injected with Eap was significantly decreased
compared with the number of CD18hypoCFSEþ cells in the
skin of buffer controls (Po0.0001) (Figure 6b). These data
provide direct evidence that Eap effectively inhibits T-cell
recruitment to the inflamed skin, and this process is critical
for the resolution of the psoriasiform skin inflammation in
CD18hypo mice.
DISCUSSION
Psoriasis is recognized as an inflammatory skin disorder that
is induced and sustained by T cells (Schon et al., 1997;
Conrad et al., 2007). A critical role for T cells in the
pathogenesis of psoriasis is supported by several lines of
evidence including the fact that psoriasis can be induced in
severe combined immunodeficient mouse xenograft model
by injection of T cells or immunocytes from psoriasis patients
(Schon et al., 1997; Nickoloff and Nestle, 2004; Sano et al.,
2005). Recently, the importance of a new lineage of
proinflammatory T helper cells producing IL-17, named
Th17 cells in autoimmunity including psoriasis has been
recognized (Weaver et al., 2007; Lowes et al., 2008; Di
Cesare et al., 2009). Furthermore, IL-23, an essential initiating
cytokine in the development of autoimmunity, has been
linked to the development and maintenance of Th17 cells (Di
Cesare et al., 2009). In addition, genome-wide scan analy-
sis reveals an association of psoriasis with IL-23 most likely
representing a priority target for the treatment of psoriasis
patients (Nair et al., 2009). Interestingly, we found increased
IL-23 (Wang et al., 2009) and IL-17 (Figure S1) expression in
affected skin derived from CD18hypo mice, indicating that the
IL-23/Th17 pathway may be involved in pathogenesis of the
CD18hypo mouse model of psoriasis. However, its causal role
in the psoriasiform skin disease in this model needs to
be further studied. The recruitment of pathogenic T cells,
including Th17 cells, is causal for the development
of psoriasis in humans and animal models of psoriasis
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(Nickoloff and Wrone-Smith, 1999; Kess et al., 2003; Harper
et al., 2009; van der Fits et al., 2009). This event is
coordinated by chemokines, cytokines, and most importantly
by the regulated expression of adhesion molecules on the
immune cells and the activated endothelium involving the
interaction of LFA-1–ICAM-1 (Helena Yusuf-Makagiansar,
2002).
Although overexpression of ICAM-1, VCAM-1, ICAM-2,
and E-selectin has repetitively been reported in psoriasis
(Horrocks et al., 1991; Terajima et al., 1998), the trafficking
of T cells into inflamed tissues may be less dependent on
ICAM-2 and E-selectin in proinflammatory conditions (Ger-
win et al., 1999; Eom et al., 2005). However, future studies
on the murine CD18hypo psoriasis model need to experimen-
tally rule out any influence of Eap on ICAM-2 and E-selectin
in vitro and in vivo. Importantly, enhanced ICAM-1 expres-
sion in psoriatic plaques facilitates T-cell extravasation,
adhesion to keratinocytes, and activation of T lymphocytes
through the interaction with LFA-1 (Dustin et al., 1988). The
experimental therapies for psoriasis, particularly Abs target-
ing LFA-1 or its ligands that interfere with the LFA-1–ICAM
adhesion mechanism, would attenuate a broad range of
T-cell-mediated reactions in vitro and in animal models
(Krensky et al., 1983; Dustin and Springer, 1988; Nakakura
et al., 1993; Gordon et al., 1995). Although LFA-1 blockade
is predicted to produce less global immune suppression
compared with other types of interventions, including T-cell
immunosuppressants and T-cell depleting agents (Nickoloff
et al., 1990), the withdrawal of anti-LFA-1 treatment
(efalizumab) presents a risk for generalized pustular psoriasis
(Gaylor and Duvic, 2004). In addition, inhibition of the
function of LFA-1 by efalizumab in psoriasis patients induces
a unique state of T-cell hyporesponsiveness (Guttman-Yassky
et al., 2008). Thus, anti-LFA-1 treatment may also decrease
the suppressive function of Treg cells, which have been
identified as key players in the control of T-cell-mediated
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Figure 6. Extracellular adherence protein (Eap) blocks T-cell recruitment to inflamed skin in affected CD18 hypomorphic (CD18hypo) mice. Responder T
(Tresp) cells were purified from spleens of CD18hypo mice using magnetic-activated cell sorting (MACS). 5–10 106 Tresp cells were labeled with
carboxyfluorescein succinimidyl ester (CFSE) and adoptively transferred i.v. into affected CD18hypo mice. Following adoptive transfer of CFSE-labeled Tresp
cells, 50mg Eap or buffer was injected intraperitoneally into affected CD18hypo recipients every day. (a) FACS analysis was performed to measure numbers
of CFSE-labeled Tresp cells from blood of affected recipients at day 5. (b) To quantify transferred CD18hypo Tresp cells in the skin of affected CD18hypo
recipients treated with Eap or buffer, 7 days after adoptive transfer, the positively stained cells with CFSE in ear of recipient mice were counted. For all
measurements, the median of cells counted in 20 high-power fields (n¼ 7) is presented. Original magnification  40. Bar¼20 mm. e, epidermis; d, dermis;
h, hair follicle. Dotted lines indicate the border between epidermis and dermis. One representative experiment out of four independent experiments is
shown. *Po0.05 by Student’s t-test.
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autoimmune processes (Sakaguchi, 2000). In fact, we
recently found that anti-LFA-1 treatment resulted in a
decrease in the suppressive function of Treg cells in mice
(Wang et al., 2008), a finding which may also have relevance
for human psoriasis. As mentioned, treatment with efalizu-
mab can induce a pustular relapse of psoriasis in some
patients, which may be due to an inhibition of the education
of Treg with a lack of suppressive function of pathogenic
Tresp cells, which upon decreasing efalizumab concentra-
tions may rush into the skin and—if uncontrolled by Treg
cells—amplify the psoriatic skin disease. Design of specific
targeting therapies to increase the efficacy and reduce the risk
of potential side effects is a demanding request in the
development of targeting therapies. Our study clearly
indicates that the potent antiinflammatory S. aureus-derived
Eap inhibits the recruitment of pathogenic T cells to the
inflamed skin without perturbing the activation and/or
proliferation of distinct T-cell subsets, and thus, Eap may
provide the basis for the development of such promising
therapeutic approaches for the treatment of psoriasis.
We have shown that Eap mainly controls the recruitment
of pathogenic T cells into inflamed skin in the CD18hypo
murine psoriasis model, leading to the resolution of the
disease. This conclusion is based on following observations.
First, ICAM-1 was found be highly expressed on endothelial
cells, thus facilitating the binding and extravasation of
pathogenic T cells. Recombinant Eap has been shown to
specifically target LFA-1–ICAM-1 but not VLA-4–VCAM-1-
mediated T-cell recruitment in a mouse model of experi-
mental autoimmune encephalomyelitis (Xie et al., 2006).
Second, as opposed to a strong inhibitory effect of Eap
(20 mgml1) on cluster formation between DC and Tresp or
Treg-cell subsets in mixed lymphocyte reactions in vitro,
using Eap at concentrations of 50 and 100mgml1, we did
not observe that recombinant Eap inhibited proliferation of
either Tresp or Treg cells in vivo, strongly indicating that
recombinant Eap at proper concentration has no inhibitory
effects on the activation of different T-cell subsets in mice.
Third, Eap markedly reduced infiltration of pathogenic Tresp
cells into the inflamed skin, and almost completely reversed
the clinical symptoms in CD18hypo mice.
Our data show that the interaction of LFA-1–ICAM-1 is
involved in the Ag presentation process in vitro. However,
in vivo, we did not detect any decrease in the proliferation of
adoptively transferred Treg and Tresp cells in recipient
CD18wt mice treated with Eap in a graft versus host model.
This indicates that Eap most likely does not interfere with the
education and activation of Treg and Tresp cells by DCs
in vivo. The therapeutic effect of Eap leading to the resolution
of the psoriasiform skin disease in CD18hypo mice rather
occurs through interfering with the LFA-1–ICAM-1 adhesion
pathway that mediates T-cell recruitment and is due to its
inhibitory effect on transendothelial migration (Xie et al.,
2006).
The finding of a1b1
þ epidermal T cells as essential
elements of psoriatic lesion formation in the AGR-Hu animal
model offers a previously unknown view of the pathogenesis
of psoriasis (Conrad et al., 2007). However, the accumulation
of a1b1
þ epidermal T cells in the epidermis is dependent on
an early activation and/or proliferation of dermal T cells in
psoriasis, suggesting dermal T cells to have a critical role in
the activation and expansion of a1b1
þ epidermal T-cell
subset, in particular their migration into epidermis (Nestle
et al., 2005; Conrad et al., 2007). In this regard, blocking of
T-cell recruitment to inflamed tissue by Eap may also prevent
the activation of a1b1
þ epidermal T cells, thus leading to the
resolution of the psoriasiform skin disease in the murine
CD18hypo model.
The reason for the observed discrepancy between the
in vitro and in vivo data on the effect of Eap on the activation
of distinct T-cell subsets remains to be characterized. It was
suggested that the requirement for distinct adhesion mole-
cules and other ligands may differ, depending on the two-
dimensional or three-dimensional surfaces of DCs and T cells
(Lammermann et al., 2008). Nevertheless, as Eap markedly
inhibits extravasation of pathogenic Tresp cells, it is likely
that Eap binding to ICAM-1 on endothelial cells has a major
role in the successful treatment of the psoriasiform dermatitis
in vivo.
Several strategies targeting T-cell function and/or traffick-
ing have successfully been used for the treatment of psoriasis
(Abrams et al., 2000; Gottlieb et al., 2000; Mrowietz et al.,
2000; Ellis and Krueger, 2001). In this regard, administration
of humanized Abs to CD25 (Mrowietz et al., 2000) or a fusion
protein composed of human IL-2 and fragments of diphtheria
toxin (DAB389IL-2) (Gottlieb et al., 1995), selectively block
the growth of activated T lymphocytes in advanced psoriasis.
Targeting CD4 with a humanized mAb (OKTcdr4a) resulted
in resolution in patients with moderate to severe psoriasis
vulgaris (Gottlieb et al., 2000). Treatment with alefacept
(anti-CD2 mAb) that targets effector memory T cells in
psoriasis vulgaris leads to improvement of patients with
chronic plaque psoriasis (Chamian et al., 2007). Alefacept
selectively targets CD45ROþ memory effector T cells,
suggesting that the memory effector T cells have a role in
the pathogenesis of psoriasis (da Silva et al., 2002; Chamian
et al., 2005, 2007). CTLA4Ig, a fusion protein that binds to
B7–1 and B7–2 molecules on the surface of Ag-presenting
cells, inhibits the CD28/B7-mediated costimulatory signal for
T-cell activation. Administration of CTLA4Ig is successful in
improvement of psoriatic disease activity (Abrams et al.,
2000). Finally, efalizumab (anti-LFA-1) neutralizes the LFA-1
function on T cells and, thus, LFA-1–ICAM-1 binding
(Gottlieb et al., 2002). All these strategies are either char-
acterized by a state of almost complete paralysis of all
activated T cells with an increased susceptibility to infection,
and possibly, an increase in tumor incidence and progres-
sion, or, as it is the case for anti-LFA-1, by severe pustular
relapse of psoriasis in some patients (Gaylor and Duvic,
2004). These relapses are most likely due to anti-LFA-1,
which decreases the suppressive function of Treg cells for the
control of psoriatic inflammation (Wang et al., 2008).
Our data show that administration of Eap inhibits the
extravasation of T cells in vivo, leads to an increase in
circulating T lymphocytes in the blood, and a decrease in
T cell emigration into skin. This is in line with the recent
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finding that percentages of circulating T cells that expressed
cutaneous lymphocyte-associated antigen, a predominant skin-
homing marker, markedly increased during treatment of
atopic dermatitis with efalizumab, suggesting that the main
function of efalizumab is to block T-cell migration (Harper
et al., 2007). The impairment of T-cell migration into tissue
may cause reactivation of the common polyomavirus JC in the
central nervous system of immunocompromised individuals
designated as progressive multifocal leukoencephalopathy
(Sterry et al., 2009). Therefore, future studies are essentially
required to define whether blocking of T-cell migration into
skin by Eap has similar potential drawbacks as efalizumab.
The major finding of this study is that Eap targets ICAM-1,
which is predominantly upregulated on the inflamed
endothelium in psoriatic lesions (Nickoloff et al., 1990;
Watabe et al., 2007), whereas Abs against LFA-1 (efalizumab)
target a constitutively expressed integrin on T lymphocytes. In
this regard, Eap seems to interfere specifically with LFA-
1–ICAM-1-mediated transendothelial migration (Xie et al.,
2006) with no inhibitory effect of T-cell activation and/or
proliferation responses in vivo. By contrast, anti-LFA-1
treatment induces T-cell hyporesponsiveness (Guttman-Yass-
ky et al., 2008) that might be harmful for the proper
immunosuppressive function of Treg cells against pathogenic
T cells in autoimmunity (Wang et al., 2008). In support of this
is our finding that wt levels of CD18 (LFA-1) expression on
Treg cells are required for functional synapse formation
between DCs and Treg cells to educate Treg cells, which
effectively exert their suppressive function on activated
pathogenic Tresp cells (Wang et al., 2008). By contrast, wt
levels of CD18 on Tresp cells are not required at all for the
formation of the immune synapse between DCs and Tresp
cells for their activation. In conclusion, our study provides
evidence that the LFA-1–ICAM-1 interaction is causally
involved in the pathogenesis of psoriasiform skin inflamma-
tion in CD18hypo mouse model of psoriasis, and targeting
ICAM-1 to block T transmigration by Eap may, therefore,
represent a potential therapeutic strategy for psoriasis with
less side effects regarding immunosuppression and relapse.
MATERIALS AND METHODS
Mice
Mice with a hypomorphic mutation of the CD18 gene (CD18hypo)
were genotyped by Southern analysis (Wilson et al., 1993). CD18þ /þ
littermates (CD18wt) resulting from heterozygote crosses served as wt
controls. Both affected CD18hypo mice with a strong psoriasiform
phenotype and healthy CD18hypo mice that did not show any
psoriasiform skin disease were used. All mice were kept under
specific pathogen-free conditions. All experiments were performed
in accordance with the guidelines for animal experimentation
approved by the Regierungspraesidium, Tuebingen, Germany.
Cell isolation
Treg cells or Tresp cells were isolated from spleens of CD18wt mice
using the CD4þCD25þ Regulatory T Cell Isolation Kit (Miltenyi,
Bergisch Gladbach, Germany), to be used for in vivo injections and
cultures. Magnetic-activated cell sorting-sorted CD4þCD25þ or
CD4þCD25 population was 491% pure, as determined by FACS.
In vivo transfer assays
To address whether adoptive transfer of Tresp cells elicits the
psoriasiform skin disease, 5–10 106 sorted Tresp cells derived from
pooled spleens of CD18wt or affected CD18hypo mice were
transferred i.v. into healthy CD18hypo mice. At 10 days after transfer,
The development of disease was determined by assessment of the
clinical picture. In some experiments, 1 106 Treg or Tresp cells
derived from C57BL/6J CD18wt (H-2b) mice were labeled with 2 mM
CFSE in complete medium for 8minutes at 37 1C in the dark and then
washed thrice with 1 phosphate-buffered saline. Subsequently,
these CFSE-labeled Treg or Tresp cells were injected intraperitone-
ally into PL/J CD18wt (H-2u) mice. Immediately after injection of
Treg or Tresp cells, 50 mg Eap or buffer was injected intraperitoneally
into PL/J CD18wt recipients every day. After 3 days, cells in the peri-
toneal cavity of each recipient were harvested by lavage with 5ml
RPMI/2mM EDTA, stained and assessed by FACS for CD25 expres-
sion and proliferation of CFSE-labeled cells (Firan et al., 2006).
Immunohistochemical analysis
Frozen cryosections of ears and skin were fixed in ice-cold acetone
for 10minutes before staining. To detect CD4þ T cells, murine
macrophages, TNF-a, CD31, ICAM-1, MCP-1, and Ki67, FITC-con-
jugated rat anti-mouse CD4 (Serotec, Oxford, UK, clone: YTS191.1),
Alexa 488-conjugated rat anti-mouse F4/80 (Caltag Laboratories,
Burlingame, CA, clone: CI:A3–1), anti-mouse TNF-a (BD Pharmingen,
San Diego, CA, clone: MP6-XT22) in conjunction with streptavidin
Cy3 conjugate (Dianova, Toronto, Canada), anti-mouse CD31
(clone: MEC 13.3, BD Pharmingen) in conjunction with goat anti-
rat Alexa Fluor 555 (Invitrogen), anti-mouse ICAM-1 (clone: 3E2, BD
Pharmingen) in conjunction with goat anti-hamster Alexa Fluor488
(Invitrogen), anti-mouse MCP-1 (Abcam, Cambridge, UK) in conjun-
ction with goat anti-rabbit Alexa Fluor488 (Invitrogen), and anti-
mouse Ki67 (Abcam) in conjunction with goat anti-rabbit Alexa
Fluor555 (Invitrogen) were used. 40,6-Diamidino-2-phenylindole
(DAPI) (Fluka, Seelze, Germany) was used to stain nuclei. All Abs
were diluted in a 1% antibody diluent (Dako, Catalog No.: S3022).
Immunohistochemistry was performed using a previously described
protocol (Pasparakis et al., 2002). Immunostainings were analyzed
with a fluorescence microscope (Zeiss Axioskop 2 plus, Zeiss). The
positively stained cells were counted. For all measurements, the
median of specifically stained cells counted in 15 high-power fields
is presented (n¼ 5).
Administration of Eap
Recombinant Eap was prepared as previously described (Xie et al.,
2006). Eap was stored at 80 1C before reconstitution in 1
phosphate-buffered saline as buffer. Mice were administered
intraperitoneally with recombinant Eap at a dose of 50 mg per
200ml daily for the indicated time period. Control mice were treated
identically with 200 ml buffer. The disease severity was determined
by assessment of the clinical picture using an adapted PASI score, as
previously described (Kess et al., 2003). For CD18hypo mice, the PASI
score was modified accordingly: 0¼ no symptoms; 1¼ slight
erythema of the ears; 2¼ strong erythema of the ears; 3¼ slight hair
loss on the head; 4¼ extensive hair loss including the trunk;
5¼ slight hair loss, isolated scaling; 6¼ extensive hair loss, isolated
scaling; 7¼ extensive hair loss, widespread slight scaling;
8¼moderate scaling of a large area of the body; 9¼widespread
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hair loss, strong scaling of a few smaller areas; 10¼ extensive hair
loss, extensive scaling of a large area of the body.
Mixed lymphocyte reaction
To detect whether Eap disrupts Ag-induced activation of
T cells by allogeneic irradiated DCs (irradiated with 30Gy) of
C57BL/6J (H-2b) mice, magnetic-activated cell sorting-sorted
CD4þCD25þ Treg or CD4þCD25 Tresp cells derived from
CD18wt PL/J (H-2u) mice that were co-cultured in flat bottom 24-
well plates (NUNC, Roskilde, Denmark) with DCs in the presence of
500 or 50Uml1 recombinant murine IL-2 (Cell concepts, Umkirch,
Germany) for 7 days (Yamazaki et al., 2006). Various concentrations
of Eap were added into cultures. Cluster formation between
allogeneic DCs and Treg or Tresp cells in the presence of Eap was
assessed by counting aggregated clusters per high-power field in 100
randomly selected high-power fields (Wang et al., 2008). DCs were
prepared as previously published (Yamazaki et al., 2006).
FACS analysis
The following mAbs were used for flow cytometry: Ag-presenting
cells or PerCP-conjugated rat anti-mouse CD4 (clone: RM4-5), Ag-
presenting cells or PerCP-conjugated rat anti-mouse CD8
(clone: RM4-5), phycoerythrin-conjugated rat anti-mouse IL-17A
(clone: TC11-18H10) (all BD Pharmingen); phycoerythrin-conju-
gated rat anti-mouse CD25 (clone: PC61, eBioscience, San Diego,
CA). Cells were isolated from blood, spleen, skin-draining lymph
nodes of CD18wt and CD18hypo mice for FACS analysis as described
(Wang et al., 2006). Single cell suspension of skin was freshly
prepared for FACS analysis, as previously indicated (Ebert et al.,
2006). Isotype controls were used for all measurements.
Statistical analysis
Quantitative data is presented as mean values±standard deviation
(SD). Statistical significance was determined by means of the two-
tailed Student’s t-test, or the Mann–Whitney U-test in cases of a non-
Gaussian distribution. Differences were considered to be statistically
significant at values of *Po0.05, **Po0.01.
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